401 related articles for article (PubMed ID: 27732937)
1. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
[TBL] [Abstract][Full Text] [Related]
3. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
7. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
Takada H; Imadome KI; Shibayama H; Yoshimori M; Wang L; Saitoh Y; Uota S; Yamaoka S; Koyama T; Shimizu N; Yamamoto K; Fujiwara S; Miura O; Arai A
PLoS One; 2017; 12(3):e0174136. PubMed ID: 28346502
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection.
Zhang Y; Ohyashiki JH; Takaku T; Shimizu N; Ohyashiki K
Br J Cancer; 2006 Feb; 94(4):599-608. PubMed ID: 16449999
[TBL] [Abstract][Full Text] [Related]
9. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
10. Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T cell lymphoma cells.
Ian MX; Lan SZ; Cheng ZF; Dan H; Qiong LH
Cancer Biol Ther; 2008 Oct; 7(10):1602-6. PubMed ID: 18769118
[TBL] [Abstract][Full Text] [Related]
11. Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile.
Cabrera ME; Eizuru Y; Itoh T; Koriyama C; Tashiro Y; Ding S; Rey S; Akiba S; Corvalan A
J Clin Pathol; 2007 Jun; 60(6):656-60. PubMed ID: 16775124
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
13. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
[TBL] [Abstract][Full Text] [Related]
14. The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.
Suzuki M; Takeda T; Nakagawa H; Iwata S; Watanabe T; Siddiquey MN; Goshima F; Murata T; Kawada J; Ito Y; Kojima S; Kimura H
Front Microbiol; 2015; 6():280. PubMed ID: 25914683
[TBL] [Abstract][Full Text] [Related]
15. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl-2 suppression in Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells, but not in EBV-positive natural killer cell lymphoma cells.
Noguchi T; Ikeda K; Yamamoto K; Yoshida I; Ashiba A; Tsuchiyama J; Shinagawa K; Yoshino T; Takata M; Harada M
Br J Haematol; 2001 Jul; 114(1):84-92. PubMed ID: 11472349
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
[TBL] [Abstract][Full Text] [Related]
18. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15.
Ishii H; Takahara M; Nagato T; Kis LL; Nagy N; Kishibe K; Harabuchi Y; Klein E
Int J Cancer; 2012 Jan; 130(1):48-58. PubMed ID: 21618217
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
